Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nervgen Pharma Corp (NGEN.VN)

Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 190,890
  • Shares Outstanding, K 70,180
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,382 K
  • 60-Month Beta 0.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.28
Trade NGEN.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.38
  • Most Recent Earnings $-0.11 on 08/22/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.500 +9.60%
on 09/12/24
3.060 -10.46%
on 08/29/24
-0.100 (-3.52%)
since 08/20/24
3-Month
2.220 +23.42%
on 06/21/24
3.310 -17.22%
on 08/07/24
+0.460 (+20.18%)
since 06/20/24
52-Week
1.580 +73.42%
on 12/14/23
3.980 -31.16%
on 02/05/24
+0.710 (+34.98%)
since 09/20/23

Most Recent Stories

More News
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

Vancouver, British Columbia--(Newsfile Corp. - September 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024Protocol being amended to enhance enrollment and lessen burden on participants in the subacute cohortNVG-300 advanced into preclinical...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)
NervGen Pharma Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - August 2, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the treatment...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)
NervGen Pharma Appoints Neil Klompas to Board of Directors

Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGenLeadership appointment supports the company's mission to advance NVG-291 after the completion...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

New molecule demonstrates efficacy in a challenging SCI modelExpanding pipeline into new indications of ischemic stroke and ALSVancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)
NervGen Pharma Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment...

NGENF : 2.0000 (-0.29%)
NGEN.VN : 2.740 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's...

See More

Key Turning Points

3rd Resistance Point 2.813
2nd Resistance Point 2.787
1st Resistance Point 2.753
Last Price 2.740
1st Support Level 2.693
2nd Support Level 2.667
3rd Support Level 2.633

See More

52-Week High 3.980
Fibonacci 61.8% 3.063
Fibonacci 50% 2.780
Last Price 2.740
Fibonacci 38.2% 2.497
52-Week Low 1.580

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar